CN105315362B - 用于制备具有降低的溶解氧的水平的人白蛋白的方法 - Google Patents
用于制备具有降低的溶解氧的水平的人白蛋白的方法 Download PDFInfo
- Publication number
- CN105315362B CN105315362B CN201510264800.9A CN201510264800A CN105315362B CN 105315362 B CN105315362 B CN 105315362B CN 201510264800 A CN201510264800 A CN 201510264800A CN 105315362 B CN105315362 B CN 105315362B
- Authority
- CN
- China
- Prior art keywords
- albumin
- albumin solution
- solution
- dissolved oxygen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 239000001301 oxygen Substances 0.000 title claims abstract description 44
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 44
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 17
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 17
- 102000009027 Albumins Human genes 0.000 claims abstract description 144
- 108010088751 Albumins Proteins 0.000 claims abstract description 144
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 61
- 238000009928 pasteurization Methods 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 210000002381 plasma Anatomy 0.000 claims description 15
- 239000001307 helium Substances 0.000 claims description 12
- 229910052734 helium Inorganic materials 0.000 claims description 12
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 12
- 239000011261 inert gas Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 239000012298 atmosphere Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 230000005587 bubbling Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 54
- 239000000523 sample Substances 0.000 description 29
- 230000003647 oxidation Effects 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000004381 surface treatment Methods 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108010004546 mercaptoalbumin Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 206010020852 Hypertonia Diseases 0.000 description 3
- 229920005556 chlorobutyl Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005184 irreversible process Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108010059904 nonmercaptalbumin Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- -1 mercaptan compound Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940116191 n-acetyltryptophan Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001581 pretranslational effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- SDLBJIZEEMKQKY-UHFFFAOYSA-M silver chlorate Chemical compound [Ag+].[O-]Cl(=O)=O SDLBJIZEEMKQKY-UHFFFAOYSA-M 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000000626 sulfinic acid group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430824 | 2014-05-29 | ||
| ES201430824A ES2524516B1 (es) | 2014-05-29 | 2014-05-29 | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105315362A CN105315362A (zh) | 2016-02-10 |
| CN105315362B true CN105315362B (zh) | 2019-10-25 |
Family
ID=52003454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510264800.9A Active CN105315362B (zh) | 2014-05-29 | 2015-05-22 | 用于制备具有降低的溶解氧的水平的人白蛋白的方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10350274B2 (OSRAM) |
| EP (1) | EP2952203B9 (OSRAM) |
| JP (3) | JP2015224251A (OSRAM) |
| KR (1) | KR101960729B1 (OSRAM) |
| CN (1) | CN105315362B (OSRAM) |
| AR (1) | AR100618A1 (OSRAM) |
| AU (1) | AU2015202413B2 (OSRAM) |
| BR (1) | BR102015012091A8 (OSRAM) |
| CA (1) | CA2890642C (OSRAM) |
| CL (1) | CL2015001446A1 (OSRAM) |
| ES (2) | ES2524516B1 (OSRAM) |
| HU (1) | HUE031823T2 (OSRAM) |
| IL (1) | IL238898B (OSRAM) |
| MX (1) | MX362869B (OSRAM) |
| MY (1) | MY171771A (OSRAM) |
| NZ (1) | NZ708537A (OSRAM) |
| PL (1) | PL2952203T3 (OSRAM) |
| PT (1) | PT2952203T (OSRAM) |
| RU (1) | RU2657578C2 (OSRAM) |
| SG (1) | SG10201504137PA (OSRAM) |
| TW (1) | TWI607018B (OSRAM) |
| ZA (1) | ZA201503539B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
| ES2975517T3 (es) | 2016-04-28 | 2024-07-08 | Alkahest Inc | Fracciones de plasma como terapia para el cáncer de timo |
| SG11201901273TA (en) | 2016-08-18 | 2019-03-28 | Alkahest Inc | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| CN117899111A (zh) | 2017-04-26 | 2024-04-19 | 万能溶剂有限公司 | 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案 |
| KR20210024196A (ko) | 2018-07-20 | 2021-03-04 | 알카헤스트 인코포레이티드 | 혈장 및 혈장 산물로 인지 및 운동 장애를 치료하기 위한 투여 요법 |
| UA128648C2 (uk) | 2018-10-26 | 2024-09-18 | Алкахест, Інк. | Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення |
| CN109627322A (zh) * | 2019-01-07 | 2019-04-16 | 中国科学院过程工程研究所 | 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法 |
| CA3151943A1 (en) | 2019-11-04 | 2021-05-14 | Viktoria Kheifets | Blood plasma fractions for use in muscle regeneration |
| EP4061384A4 (en) | 2019-11-20 | 2023-11-01 | Alkahest, Inc. | BLOOD PLASMA FRACTIONS FOR USE IN LIVER REGENERATION |
| JP2026511640A (ja) | 2023-03-29 | 2026-04-14 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | ＦｃεＲＩβ自己抗体のレベルが低減された血漿製剤の組成物および調製方法 |
| CN118166053B (zh) * | 2024-03-15 | 2025-02-07 | 通化安睿特生物制药股份有限公司 | 一种制备低o-糖基化水平的重组人白蛋白的方法 |
| WO2025230830A1 (en) | 2024-04-29 | 2025-11-06 | Alkahest, Inc. | Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
| EP1245217A2 (en) * | 2001-03-27 | 2002-10-02 | Nipro Corporation | Plastic container containing albumin solution |
| EP1538151A1 (en) * | 2003-08-28 | 2005-06-08 | Nipro Corporation | Artificial oxygen carrier and production method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| JPH07126182A (ja) * | 1993-10-27 | 1995-05-16 | Green Cross Corp:The | 組換えヒト血清アルブミン製剤の滅菌方法 |
| SE9402119D0 (sv) * | 1994-06-16 | 1994-06-16 | Pharmacia Ab | Solution |
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| JP4254117B2 (ja) * | 2001-03-27 | 2009-04-15 | ニプロ株式会社 | アルブミン溶液収容プラスチック容器 |
| JP4225416B2 (ja) * | 2001-06-29 | 2009-02-18 | 旭化成ファーマ株式会社 | タンパク質製剤の安定性を改善する方法 |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| RS52459B (sr) * | 2006-02-07 | 2013-02-28 | Shire Human Genetic Therapies Inc. | Stabilizovane kompozicije glukocerebrozidaze |
| ES2294976B1 (es) * | 2007-11-12 | 2008-12-16 | Grifols, S.A. | "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion". |
| JP5990880B2 (ja) * | 2011-08-31 | 2016-09-14 | 東レ株式会社 | 有用タンパク質組成物およびその製造方法 |
| CN102816230B (zh) * | 2012-08-27 | 2014-02-12 | 同路生物制药股份有限公司 | 人血白蛋白的制备方法 |
| ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
-
2014
- 2014-05-29 ES ES201430824A patent/ES2524516B1/es not_active Expired - Fee Related
-
2015
- 2015-04-01 PL PL15382164T patent/PL2952203T3/pl unknown
- 2015-04-01 ES ES15382164.0T patent/ES2601137T3/es active Active
- 2015-04-01 PT PT153821640T patent/PT2952203T/pt unknown
- 2015-04-01 HU HUE15382164A patent/HUE031823T2/en unknown
- 2015-04-01 EP EP15382164.0A patent/EP2952203B9/en active Active
- 2015-05-01 CA CA2890642A patent/CA2890642C/en active Active
- 2015-05-06 AU AU2015202413A patent/AU2015202413B2/en active Active
- 2015-05-15 MY MYPI2015701570A patent/MY171771A/en unknown
- 2015-05-18 RU RU2015118453A patent/RU2657578C2/ru active
- 2015-05-19 IL IL238898A patent/IL238898B/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03539A patent/ZA201503539B/en unknown
- 2015-05-21 MX MX2015006407A patent/MX362869B/es active IP Right Grant
- 2015-05-22 CN CN201510264800.9A patent/CN105315362B/zh active Active
- 2015-05-26 BR BR102015012091A patent/BR102015012091A8/pt not_active IP Right Cessation
- 2015-05-26 TW TW104116876A patent/TWI607018B/zh not_active IP Right Cessation
- 2015-05-26 SG SG10201504137PA patent/SG10201504137PA/en unknown
- 2015-05-27 AR ARP150101653A patent/AR100618A1/es active IP Right Grant
- 2015-05-27 NZ NZ708537A patent/NZ708537A/en not_active IP Right Cessation
- 2015-05-28 US US14/724,649 patent/US10350274B2/en active Active
- 2015-05-28 JP JP2015108569A patent/JP2015224251A/ja active Pending
- 2015-05-28 KR KR1020150074568A patent/KR101960729B1/ko active Active
- 2015-05-28 CL CL2015001446A patent/CL2015001446A1/es unknown
-
2018
- 2018-04-27 JP JP2018086673A patent/JP2018115210A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074749A patent/JP2020111614A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
| EP1245217A2 (en) * | 2001-03-27 | 2002-10-02 | Nipro Corporation | Plastic container containing albumin solution |
| EP1538151A1 (en) * | 2003-08-28 | 2005-06-08 | Nipro Corporation | Artificial oxygen carrier and production method thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI607018B (zh) | 具有降低的溶氧濃度之人類白蛋白的製造方法 | |
| Greene et al. | Physical evidence for transferrins as single polypeptide chains | |
| Alberty | A study of the variation of the average isoelectric points of several plasma proteins with ionic strength. | |
| Weihing et al. | Acanthamoeba actin. Isolation and properties | |
| Yurewicz et al. | Macromolecular composition of Xenopus laevis egg jelly coat | |
| ES2869895T3 (es) | Método de purificación de proteínas | |
| CN108524929B (zh) | 一种狂犬病疫苗的生产方法 | |
| CN113474366A (zh) | 产生优特克单抗的方法 | |
| Pozzi et al. | Metal ions bound to the human milk immunoglobulin A: Metalloproteomic approach | |
| US8716440B2 (en) | Method of liberating and recovering peptide | |
| Carnarius et al. | Green fluorescent protein changes the conductance of connexin 43 (Cx43) hemichannels reconstituted in planar lipid bilayers | |
| Capaldi | The structure of erythrocyte membranes: a partial separation of intrinsic and extrinsic membrane proteins | |
| Sanders | Isolation and characterization of the nonhistone chromosomal proteins of developing avian erythroid cells | |
| CN1749274B (zh) | 一种新的重组人干扰素α2b的分离纯化方法 | |
| DE60304040T2 (de) | Methode zur identifizierung und eliminierung von t-zell epitopen | |
| Diéguez-Casal et al. | High resolution clear native electrophoresis is a good alternative to blue native electrophoresis for the characterization of the Escherichia coli membrane complexes | |
| RU2391354C1 (ru) | Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой | |
| CN106478790A (zh) | 肽的游离方法及回收方法、以及肽游离剂及试剂盒 | |
| Ballard et al. | The Macromolecular Composition of Xenopus laevis Egg Jelly Coat? | |
| Bhushan et al. | Subunit structure of glycinin and its molecular species based on RP‐HPLC, gel electrophoresis and SEC studies | |
| Nagabhushan et al. | Macroscale production of crystalline interferon alfa‐2b in microgravity on STS‐52 | |
| Ebrahim-Damavandi et al. | Reducing allergenicity of bovine beta lactoglobulin throughout Cu complexes | |
| Vahidzadeh et al. | Studies on the interaction of colchicine and human serum albumin by the measurement of zeta-potential | |
| Fleck | Studies in plasma protein metabolism | |
| Evans | INSIDE-OUT RH NEGATIVE ERYTHROCYTES ARE RH POSITIVE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |